false 0001659617 0001659617 2025-04-09 2025-04-09
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 9, 2025
 
a01.jpg
 
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
001-37758
47-4671997
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)
 
5300 Memorial Drive, Suite 950, Houston, TX 77007
(Address of principal executive offices and zip code)
 
(713) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                    Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
MBRX
The NASDAQ Stock Market LLC
 
 
 
 
Item 8.01. Other Events.
 
Moleculin Biotech Inc., (the “Company”) convened its Special Meeting of Stockholders (the “Special Meeting”) at the Company’s offices located at 5300 Memorial Drive, Suite 950, Houston, Texas 77007, on April 9, 2025, at 10:00 a.m. Central Time. After counting the number of shares present in person and by proxy, it was determined that a quorum for the transaction of business at the Special Meeting was not present. A vote of shares present was held to adjourn the Special Meeting until April 25, 2025, at 10:00 a.m. Central Time, at the Company’s offices located at 5300 Memorial Drive, Suite 950, Houston, Texas 77007.
 
Therefore, the Special Meeting has been adjourned until April 25, 2025, at 10:00 a.m. Central Time, at the Company’s offices located at 5300 Memorial Drive, Suite 950, Houston, Texas 77007. All business to be transacted at the Special Meeting remains the same.
 
SIGNATURE
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MOLECULIN BIOTECH, INC.
   
 
Date: April 9, 2025
By: /s/ Jonathan P. Foster
Jonathan P. Foster
Chief Financial Officer
 
 
 
 
v3.25.1
Document And Entity Information
Apr. 09, 2025
Document Information [Line Items]  
Entity, Registrant Name MOLECULIN BIOTECH, INC.
Document, Type 8-K
Document, Period End Date Apr. 09, 2025
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37758
Entity, Tax Identification Number 47-4671997
Entity, Address, Address Line One 5300 Memorial Drive
Entity, Address, Address Line Two Suite 950
Entity, Address, City or Town Houston
Entity, Address, State or Province TX
Entity, Address, Postal Zip Code 77007
City Area Code 713
Local Phone Number 300-5160
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Title of 12(b) Security Common Stock
Trading Symbol MBRX
Security Exchange Name NASDAQ
Amendment Flag false
Entity, Central Index Key 0001659617
Grafico Azioni Moleculin Biotech (NASDAQ:MBRX)
Storico
Da Mar 2025 a Apr 2025 Clicca qui per i Grafici di Moleculin Biotech
Grafico Azioni Moleculin Biotech (NASDAQ:MBRX)
Storico
Da Apr 2024 a Apr 2025 Clicca qui per i Grafici di Moleculin Biotech